Tech firm Proscia secured $23 million in a Series B funding round as the growing Center City company, focused on driving digitization and artificial intelligence in the pathology world, continues to land major customers and expand its team.
Proscia’s AI-driven software platform Concentriq is designed to take the vast amounts of data contained in pathology slides, which have previously been difficult to access and analyze at scale, and help pathologists better diagnose and research diseases.
Proscia has now raised $35 million in venture capital since it was founded in 2014 by a team of biomedical engineers coming out of Johns Hopkins University and the University of Pittsburgh. The newest round was led by California-based Scale Venture Partners and joined in by Japanese conglomerate Hitachi’s venture fund Hitachi Ventures. Previous investors include Flybridge Capital, Emerald Development Managers and Philadelphia’s own Robin Hood Ventures.
The cash infusion from the new investors will allow Proscia to grow from its current headcount of about 40 to 70 by the end of 2021.
